<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2027">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04356508</url>
  </required_header>
  <id_info>
    <org_study_id>UW20213</org_study_id>
    <nct_id>NCT04356508</nct_id>
  </id_info>
  <brief_title>COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1</brief_title>
  <official_title>COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr Gerry Gin Wai Kwok</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Queen Mary Hospital, Hong Kong</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, controlled, single-centre pilot study of nivolumab in adult patients
      with COVID-19. This clinical study aims to evaluate efficacy of anti-PD1 antibody in relation
      to viral clearance and its safety.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 14, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Viral clearance kinetics</measure>
    <time_frame>From diagnosis to recovery, assessed up to 6 months</time_frame>
    <description>Viral load changes in NPS based on SARS-CoV-2 RT-PCR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-related adverse events of nivolumab (Intervention arm only)</measure>
    <time_frame>Up to 1 year after nivolumab dosing</time_frame>
    <description>Incidence and severity of treatment-related adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocyte kinetics</measure>
    <time_frame>On days 1, 4, 6, 8, 10 and 28 from study enrollment</time_frame>
    <description>Changes in lymphocyte counts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine kinetics</measure>
    <time_frame>On days 1, 4, 6, 8 and 10 from study enrollment</time_frame>
    <description>Changes in cytokine levels (e.g. IL-1B, IL-2, IL-6, TNFa)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of inpatient stay due to COVID-19</measure>
    <time_frame>From hospital admission to discharge, assessed up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>COVID-19</condition>
  <condition>SARS-CoV-2</condition>
  <condition>2019-nCoV</condition>
  <condition>Pneumonia, Viral</condition>
  <arm_group>
    <arm_group_label>Intervention (n=10)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab + best supportive care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-intervention (n=5)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Best supportive care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Single dose at 0.3mg/kg</description>
    <arm_group_label>Intervention (n=10)</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of COVID-19 by RT-PCR for SARS-CoV-2

          -  Clinically stable with disease severity defined as mild or moderate (mild disease is
             defined as symptoms with or without lung infiltrates on chest X-Ray or CT imaging;
             moderate disease is defined as lung infiltrates with evidence of type 1 respiratory
             failure)

          -  Asymptomatic patients may be enrolled if patients have obvious radiographic changes on
             chest or CT radiography deemed to be related to COVID-19

        Exclusion Criteria:

          -  Active cancer, rheumatological and autoimmune conditions

          -  Transplant recipients, or patients on active immunosuppressants

          -  Chronic organ impairment, or documented or suspected concomitant infections (including
             chronic viral hepatitis B and hepatitis C) other than SARS-CoV-2

          -  Lactating mothers and women who are pregnant or intending to become pregnant

          -  Acute respiratory distress syndrome, evidence of myocardial injury, disseminated
             intravascular coagulopathy, organ failure, hemophagocytosis, shock, respiratory
             distress, or need for mechanical ventilation, AICU admission, or high flow oxygen
             therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerry Gin Wai Kwok, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Mary Hospital, Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gerry Gin Wai Kwok, MBBS</last_name>
    <phone>+852-22553111</phone>
    <email>gggjerry@gmail.com</email>
  </overall_contact>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 10, 2020</study_first_submitted>
  <study_first_submitted_qc>April 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <last_update_submitted>April 17, 2020</last_update_submitted>
  <last_update_submitted_qc>April 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Queen Mary Hospital, Hong Kong</investigator_affiliation>
    <investigator_full_name>Dr Gerry Gin Wai Kwok</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>2019-nCoV</keyword>
  <keyword>Coronavirus</keyword>
  <keyword>Anti-PD1</keyword>
  <keyword>Nivolumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia, Viral</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

